规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1mg |
|
||
2mg |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
Other Sizes |
|
体外研究 (In Vitro) |
Abaloparatide(0-100 nM;40 分钟)可增加 MC3T3-E1 细胞中 β-arrestin 募集和 Gs/cAMP 信号传导[1]。 Abaloparatide (0-100 nM) 可有效且剂量依赖性地诱导 U2OS 细胞中的 PTHR1 内化,EC50 值为 0.8 nM[1]。
|
---|---|
体内研究 (In Vivo) |
在小鼠中,阿贝拉帕肽(20–80 µg/kg;皮下注射;每日一次,持续 30 天)可改善皮质结构和骨形成[1]。
|
动物实验 |
16-week-old wild-type (WT) female C57BL/6J mice[1]
20-80 µg/kg S.c.; daily for 30 days |
参考文献 |
|
分子式 |
C174H299N56O49
|
---|---|
分子量 |
3959.65
|
元素分析 |
C, 52.58; H, 7.62; N, 19.51; O, 20.29
|
CAS号 |
247062-33-5
|
相关CAS号 |
Abaloparatide TFA
|
外观&性状 |
Solid powder
|
SMILES |
O=C([C@H](CC(C)C)NC([C@H](CCCCN)NC([C@H](CCC(=O)O)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CCC(=O)O)NC([C@H](CCCNC(=N)N)NC([C@H](CCCNC(=N)N)NC([C@H](CCCNC(=N)N)NC([C@H](CC(C)C)NC([C@H](CC(=O)O)NC([C@H](CCC(N)=O)NC([C@H]([C@@H](C)CC)NC([C@H](CO)NC([C@H](CCCCN)NC(CNC([C@H](CCCCN)NC([C@H](CC(=O)O)NC([C@H](CC1=CN=CN1)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CCC(N)=O)NC([C@H](CC1=CN=CN1)NC([C@H](CCC(=O)O)NC([C@H](CO)NC([C@H](C(C)C)NC([C@H](C)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)N[C@H](C(NC(C)(C)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N)=O)C)=O)[C@@H](C)O)=O)CC1=CN=CN1)=O)CC(C)C)=O)CCCCN)=O)=O)CC(C)C
|
化学名 |
Ala-Val-Ser-Glu-His-Gln-Leu-Leu-His-Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-ArgArg-Glu-Leu-Leu-Glu-Lys-Leu-Leu-Aib-Lys-Leu-His-Thr-Ala-NH2
|
别名 |
BIM-44058; Abaloparatide acetate; BA-058; ITM-058; BIM 44058; BA 058;ITM 058; BIM44058; BA058;ITM058; trade name: Tymlos
|
HS Tariff Code |
2934.99.9001
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
|
|||
---|---|---|---|---|
溶解度 (体内) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (0.63 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (0.63 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (0.63 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 0.2525 mL | 1.2627 mL | 2.5255 mL | |
5 mM | 0.0505 mL | 0.2525 mL | 0.5051 mL | |
10 mM | 0.0253 mL | 0.1263 mL | 0.2525 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT03841058 | Recruiting | Drug: Abaloparatide Drug: Placebo |
Spinal Fusion | Hospital for Special Surgery, New York |
August 14, 2019 | Phase 2 |
NCT04626141 | Not yet recruiting | Drug: Abaloparatide Drug: Placebo |
Femoral Fractures | Daniel Horwitz | September 2023 | Phase 4 |
NCT04167163 | Recruiting | Drug: Abaloparatide | Osteoporosis Arthroplasties, Knee Replacement |
University of Wisconsin, Madison | January 10, 2020 | Phase 4 |
NCT04760782 | Recruiting | Drug: Abaloparatide Device: Hard collar immobilization |
Odontoid Fracture | David Lunardini | May 18, 2022 | Phase 2 |
NCT03710889 | Completed | Drug: Abaloparatide | Osteoporosis Osteoporosis Risk |
Radius Health, Inc. | September 20, 2018 | Phase 3 |
Effects of abaloparatide and teriparatide administration on vertebral trabecular bone architecture: Female C57BL/6J WT mice were SC injected daily, except Sunday, with vehicle or 20–80 µg/kg/day teriparatide or abaloparatide for 30 days. Physiol Rep . 2019 Oct;7(19):e14225. td> |
Effects of daily abaloparatide and teriparatide on serum Ca2+ and Pi: Female C57BL/6 WT mice were injected SC daily, except Sunday, with vehicle or 20–80 µg/kg/day teriparatide or abaloparatide for 30 days. Physiol Rep . 2019 Oct;7(19):e14225. td> |
Anabolic windows during 12 months of abaloparatide administration. J Bone Miner Res . 2017 Jan;32(1):24-33. td> |